如何降低别嘌醇所致超敏反应的发生风险?

2022-01-10 吴新安药师 吴新安药师

在2020 年 ACR 的痛风治疗指南及今年新发布的《痛风基层合理用药指南》在内的多个国内指南推荐别嘌醇作为一线降尿酸药物,但别嘌醇因可引发致死性超敏反应,令不少医生对这一药物望而却步。

在2020 年 ACR 的痛风治疗指南及今年新发布的《痛风基层合理用药指南》在内的多个国内指南推荐别嘌醇作为一线降尿酸药物,但别嘌醇因可引发致死性超敏反应,令不少医生对这一药物望而却步。

作为一线推荐药物的别嘌醇,别嘌醇安全性到底如何?又如何降低超敏反应的发生风险呢?

疑问回应

Q1别嘌醇是什么?

1.药品分类:降尿酸药。

2.适应症:用于治疗

①原发性和继发性高尿酸血症,尤其是尿酸生成过多而引起的高尿酸血症;

②反复发作或慢性痛风者;

③痛风石;

④尿酸性肾结石和(或)尿酸性肾病;

⑤有肾功能不全的高尿酸血症。

3.用法用量:

①成人:起始剂量 50mg/次、1~2次/d,每周可

递增50~100mg至200~300mg/d,分2~3次口服。

根据每2~4周监测血和尿的尿酸水平确定是否增量。

CKD1~2期患者用量不得大于800mg;CKD3~4期患者推荐剂量为50~100mg/d,用量不得超过300mg/d;CKD5期患者慎用。注意使用最低有效剂量维持血尿酸在目标水平以下的原则。 

儿童:<6 岁,50mg/次、1~3次/d;6~10 岁,100mg/次、1~3次/d。剂量可酌情调整。

4. 不良反应及处理:

可引起皮肤过敏反应及肝肾功能损伤,严重者可发生致死性剥脱性皮炎等超敏反应综合征。若皮疹广泛持久,对症治疗无效并有加重趋势或发生白细胞计数减少、血小板减少、贫血或骨髓抑制必须停药。其他胃肠道反应如恶心、呕吐、腹泻等及周围神经炎等常为一过性,停药后会消失。应从小剂量开始用药,用药期间定期检查血常规及肝肾功能,一旦出现皮疹建议立即停药。

5.药物相互作用:

①可增强抗凝药如双香豆素等或免疫抑制剂硫唑嘌呤及巯嘌呤的作用,应注意调整后者剂量。

②与氨苄西林同用,皮疹的发生率增多;

③与环磷酰胺同用,骨髓的抑制更明显;

④与尿酸化药同用,可增加肾结石形成的可能;

⑤不宜与铁剂同服。

6.特殊人群:

孕妇及哺乳期妇女用药:禁用。

儿童用药儿童用药:剂量应酌情调整。

老年患者用药:老年人应谨慎用药,并应减少一日用量。

Q2如何避免别嘌醇的超敏反应?

1.条件允许建议用药前筛查HLA‐B*5801基因。如无法进行基因筛查,应仔细询问过敏史。

2.从50 mg/d甚至更小剂量开始使用,仔细观察,一旦出现皮疹立即停药。

3.从小剂量开始给药

4.避免联合应用利尿剂

5.对于肾功能不全的患者慎重用药

6.密切关注用药后的反应

Tips:HLA-B*5801阳性的个体应用别嘌醇需要慎重,但并非不能应用。有研究发现, HLA-B*5801 阳性群体中,肾功能正常者别嘌醇导致的超敏反应综合征(AHS) 发生率不超过 2.7%,而肾功能不全者中的发生率高达 18%。因此,对于肾功能不全的个体,应用别嘌醇要慎重。ACR指南推荐,起始治疗时,别嘌醇的日剂量不应超过100mg,对于肾功能不全者,剂量应进一步调低,有研究发现,每日别嘌醇剂量不超过1.5xGFR(mg)时,可以减少 AHS的发生率。鉴于发生AHS的中位时间为 30 天,在起始治疗的第一个月,尤其应该关注有无皮疹等表现;此外,即使起始治疗的前几个月没有发生 AHS,也不能完全对AHS 放松警惕。

Q3

哪些人群适用别嘌醇?

肾功能正常且HLA-B*5801阴性的个体,应用别嘌醇相对安全。

对于HLA-B*5801阳性的个体,如果肾功能正常,发生AHS的风险高于阴性个体,但仍可尝试从小剂量起始治疗,如果肾功能不全,应尽可能避免应用别嘌醇。目前一些医疗机构无法进行HLA-B*5801 检测,针对这种情况,也可应用别嘌醇,但剂量应该从更低水平开始,每日50mg甚至隔日50mg,四周后如无不良反应发生,可根据尿酸下降情况调整用量。

Q4应用时有哪些注意事项?

1.别嘌醇不能控制痛风性关节炎的急性炎症症状,不能作为抗炎药使用。

2.别嘌醇促使尿酸结晶重新溶解时可再次诱发并加重关节炎急性期症状,故应在痛风发作缓解2-4周后方开始应用,药物治疗过程中出现痛风发作,不建议停用降尿酸药物。

3.服药期间应多饮水,并使尿液呈中性或碱性,以利尿酸排泄。

4.本品必须由小剂量开始,逐渐递增至有效量维持正常血尿酸和尿尿酸水平,以后逐渐减量,用最小有效量维持较长时间

5.如出现任何皮肤反应或其他超敏反应体征应当立即停药并及时就医。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1194427, encodeId=f4a6119442e84, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba1286668, createdName=huitailang, createdTime=Thu Feb 17 14:15:36 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984351, encodeId=f7e419843514d, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jun 14 02:04:32 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279630, encodeId=05a512e9630a3, content=<a href='/topic/show?id=28b73234215' target=_blank style='color:#2F92EE;'>#别嘌醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32342, encryptionId=28b73234215, topicName=别嘌醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Jan 12 01:04:32 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182789, encodeId=40f81182e893c, content=好东西啊值得学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/30ec60ff95c144f29d7e88e61ba9db7e/95058e87d066417181daf17bcdf446dc.jpg, createdBy=b0102305891, createdName=ms5989603601386402, createdTime=Mon Jan 10 11:14:43 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182771, encodeId=eddf1182e7174, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Mon Jan 10 10:39:20 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
    2022-02-17 huitailang

    不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1194427, encodeId=f4a6119442e84, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba1286668, createdName=huitailang, createdTime=Thu Feb 17 14:15:36 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984351, encodeId=f7e419843514d, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jun 14 02:04:32 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279630, encodeId=05a512e9630a3, content=<a href='/topic/show?id=28b73234215' target=_blank style='color:#2F92EE;'>#别嘌醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32342, encryptionId=28b73234215, topicName=别嘌醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Jan 12 01:04:32 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182789, encodeId=40f81182e893c, content=好东西啊值得学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/30ec60ff95c144f29d7e88e61ba9db7e/95058e87d066417181daf17bcdf446dc.jpg, createdBy=b0102305891, createdName=ms5989603601386402, createdTime=Mon Jan 10 11:14:43 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182771, encodeId=eddf1182e7174, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Mon Jan 10 10:39:20 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1194427, encodeId=f4a6119442e84, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba1286668, createdName=huitailang, createdTime=Thu Feb 17 14:15:36 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984351, encodeId=f7e419843514d, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jun 14 02:04:32 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279630, encodeId=05a512e9630a3, content=<a href='/topic/show?id=28b73234215' target=_blank style='color:#2F92EE;'>#别嘌醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32342, encryptionId=28b73234215, topicName=别嘌醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Jan 12 01:04:32 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182789, encodeId=40f81182e893c, content=好东西啊值得学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/30ec60ff95c144f29d7e88e61ba9db7e/95058e87d066417181daf17bcdf446dc.jpg, createdBy=b0102305891, createdName=ms5989603601386402, createdTime=Mon Jan 10 11:14:43 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182771, encodeId=eddf1182e7174, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Mon Jan 10 10:39:20 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
    2022-01-12 xugumin
  4. [GetPortalCommentsPageByObjectIdResponse(id=1194427, encodeId=f4a6119442e84, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba1286668, createdName=huitailang, createdTime=Thu Feb 17 14:15:36 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984351, encodeId=f7e419843514d, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jun 14 02:04:32 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279630, encodeId=05a512e9630a3, content=<a href='/topic/show?id=28b73234215' target=_blank style='color:#2F92EE;'>#别嘌醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32342, encryptionId=28b73234215, topicName=别嘌醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Jan 12 01:04:32 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182789, encodeId=40f81182e893c, content=好东西啊值得学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/30ec60ff95c144f29d7e88e61ba9db7e/95058e87d066417181daf17bcdf446dc.jpg, createdBy=b0102305891, createdName=ms5989603601386402, createdTime=Mon Jan 10 11:14:43 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182771, encodeId=eddf1182e7174, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Mon Jan 10 10:39:20 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
    2022-01-10 ms5989603601386402

    好东西啊值得学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1194427, encodeId=f4a6119442e84, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba1286668, createdName=huitailang, createdTime=Thu Feb 17 14:15:36 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984351, encodeId=f7e419843514d, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Jun 14 02:04:32 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279630, encodeId=05a512e9630a3, content=<a href='/topic/show?id=28b73234215' target=_blank style='color:#2F92EE;'>#别嘌醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32342, encryptionId=28b73234215, topicName=别嘌醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Jan 12 01:04:32 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182789, encodeId=40f81182e893c, content=好东西啊值得学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/30ec60ff95c144f29d7e88e61ba9db7e/95058e87d066417181daf17bcdf446dc.jpg, createdBy=b0102305891, createdName=ms5989603601386402, createdTime=Mon Jan 10 11:14:43 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182771, encodeId=eddf1182e7174, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Mon Jan 10 10:39:20 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
    2022-01-10 ms4000000408264698

    学习了

    0

相关资讯

无症状高尿酸血症,为什么建议你降尿酸?

别被“无症状”给骗了,无症状高尿酸同样也需要干预!

这位降尿酸的主力军,居然还能降低痛风患者的心梗风险高达50%!

PLOS ONE: 别嘌呤醇降低心血管疾病发病率和死亡率:一项系统回顾和荟萃分析

你以为关节痛都是类风湿惹的祸?不,这种关节痛要找TA算账

许多疾病都会导致关节痛,找准病因才能对症下药,药到病除。

APLAR痛风治疗临床实践指南VS2019年中国指南,9大项目对比,一文总结!

亚太抗风湿病联盟(APLAR)发布2021年痛风治疗临床实践指南。此指南与中国的指南又有什么异同呢?一起看看吧

超百万女性8年随访:口服避孕药、激素替代疗法需谨慎!痛风发生风险或增加!

ARTHRITIS RES THER:女性生殖因素与痛风的关系:一项针对100万绝经后女性的全国性人群队列研究